BOLERO-@ is a phase III , double-blind , randomized international trial comparing EVE @ mg/day plus EXE @ mg/day versus placebo ( PBO ) + EXE @ mg/day in postmenopausal women with HR ( + ) advanced breast cancer with prior exposure to NSAIs .